Showing 1 to 7 of 7 results
US Cuts $500 Million in mRNA Vaccine Research Funding
The US Department of Health and Human Services, led by Robert F. Kennedy Jr., slashed $500 million in mRNA vaccine research funding, citing ineffective protection against respiratory infections, despite expert consensus on the technology's life-saving role during the COVID-19 pandemic and its potent...
US Cuts $500 Million in mRNA Vaccine Research Funding
The US Department of Health and Human Services, led by Robert F. Kennedy Jr., slashed $500 million in mRNA vaccine research funding, citing ineffective protection against respiratory infections, despite expert consensus on the technology's life-saving role during the COVID-19 pandemic and its potent...
Progress
48% Bias Score
BioNTech to Acquire Curevac for $1.25 Billion
BioNTech, co-founded by Prof. Ugur Sahin and Prof. Ozlem Tureci, will acquire Curevac for $1.25 billion, strengthening its mRNA cancer treatments, with the deal expected to close by late 2025, combining their expertise in mRNA technology.
BioNTech to Acquire Curevac for $1.25 Billion
BioNTech, co-founded by Prof. Ugur Sahin and Prof. Ozlem Tureci, will acquire Curevac for $1.25 billion, strengthening its mRNA cancer treatments, with the deal expected to close by late 2025, combining their expertise in mRNA technology.
Progress
32% Bias Score
BioNTech Restructures, Shifting Focus to mRNA Cancer Therapies
BioNTech, due to reduced Covid-19 vaccine demand, will cut 250-350 jobs in Marburg and up to 150 in Idar-Oberstein, but add 800-1200 positions elsewhere, focusing on mRNA cancer therapies with a goal of market approval by 2026.
BioNTech Restructures, Shifting Focus to mRNA Cancer Therapies
BioNTech, due to reduced Covid-19 vaccine demand, will cut 250-350 jobs in Marburg and up to 150 in Idar-Oberstein, but add 800-1200 positions elsewhere, focusing on mRNA cancer therapies with a goal of market approval by 2026.
Progress
40% Bias Score
mRNA Cancer Vaccines: Promising Trials, but No Approvals Yet
Despite initial hopes after the success of mRNA COVID-19 vaccines, no mRNA cancer vaccines have received approval yet; however, several are in clinical trials, showing potential for personalized cancer treatments but facing significant hurdles.
mRNA Cancer Vaccines: Promising Trials, but No Approvals Yet
Despite initial hopes after the success of mRNA COVID-19 vaccines, no mRNA cancer vaccines have received approval yet; however, several are in clinical trials, showing potential for personalized cancer treatments but facing significant hurdles.
Progress
32% Bias Score
BioNTech to Acquire CureVac, Boosting Tübingen's Biotech Hub
BioNTech, a Mainz-based pharmaceutical company, plans to acquire its Tübingen-based rival CureVac in a multi-billion euro deal, aiming to expand mRNA-based cancer immunotherapy research and development in Tübingen, strengthening the region's biotech hub and securing high-skilled jobs.
BioNTech to Acquire CureVac, Boosting Tübingen's Biotech Hub
BioNTech, a Mainz-based pharmaceutical company, plans to acquire its Tübingen-based rival CureVac in a multi-billion euro deal, aiming to expand mRNA-based cancer immunotherapy research and development in Tübingen, strengthening the region's biotech hub and securing high-skilled jobs.
Progress
44% Bias Score
BioNTech's Oncology Push: Cancer Drug Filing Planned, Q1 Loss Reported
BioNTech, experiencing a €415.8 million net loss in Q1 2025, plans to file for U.S. approval of a uterine cancer treatment by year-end, aiming to become a leading oncology company by 2030, with a new CFO starting July 1st, 2025.
BioNTech's Oncology Push: Cancer Drug Filing Planned, Q1 Loss Reported
BioNTech, experiencing a €415.8 million net loss in Q1 2025, plans to file for U.S. approval of a uterine cancer treatment by year-end, aiming to become a leading oncology company by 2030, with a new CFO starting July 1st, 2025.
Progress
36% Bias Score
Moderna Stock Surges on Patent Win, but Weak Financials Raise Concerns
Moderna's stock jumped 16% after winning a patent infringement case against BioNTech and Pfizer, but its weak recent financial performance, including a 66% quarterly revenue drop and negative operating margins, raises concerns for investors despite a strong balance sheet.
Moderna Stock Surges on Patent Win, but Weak Financials Raise Concerns
Moderna's stock jumped 16% after winning a patent infringement case against BioNTech and Pfizer, but its weak recent financial performance, including a 66% quarterly revenue drop and negative operating margins, raises concerns for investors despite a strong balance sheet.
Progress
60% Bias Score
Showing 1 to 7 of 7 results